文献速递关节外科骨质疏松与代谢性骨病

双膦酸盐使用与骨质疏松合并膝骨关节炎患者接受全膝关节置换术风险:台湾地区全国性队列研究

Bisphosphonate Use and the Risk of Undergoing Total Knee Arthroplasty in Osteoporotic Patients with Osteoarthritis: A Nationwide Cohort Study in Taiwan.
PubMed 文献 · J Bone Joint Surg Am · 2017-01-01

该研究基于台湾地区全民健康保险研究数据库,纳入2009至2012年新诊断膝骨关节炎的骨质疏松患者,比较双膦酸盐使用者与未使用任何抗骨质疏松药物者的全膝关节置换术风险及止痛药用量。结果显示双膦酸盐使用与全膝关节置换术风险显著降低相关(校正HR 0.76,95%CI 0.69-0.83,p<0.001),且在高依从性和较长治疗时长者中效应更明显,同时双膦酸盐使用者的止痛药累积用量显著减少。

要点

  • 骨质疏松合并膝骨关节炎患者中,双膦酸盐使用与全膝关节置换术风险显著降低相关(校正HR 0.76,95%CI 0.69-0.83,p<0.001)。
  • 随访≥24个月且药物持有率≥80%者效应更显著(校正HR 0.66,p=0.048)。
  • 5年随访期间,双膦酸盐使用者的止痛药累积用量较非使用者显著减少(p<0.001,Chow检验)。

核心结论

  • 在骨质疏松合并膝骨关节炎患者中,双膦酸盐使用与全膝关节置换术风险显著降低相关,尤其在高依从性和较长治疗时长者中。
  • 双膦酸盐使用者的止痛药用量也较非使用者显著减少。

研究设计与样本

  • 台湾地区全民健康保险研究数据库的全国性队列研究,纳入2009至2012年新诊断膝骨关节炎的骨质疏松患者,分为双膦酸盐使用者(16,276例)和未使用任何抗骨质疏松药物者(123,791例)。
  • 采用药物持有率(MPR)评估依从性,MPR≥80%定义为高依从性;主要结局为接受全膝关节置换术,次要结局为止痛药使用。
  • 采用倾向评分校正的Cox比例风险模型估计双膦酸盐使用与全膝关节置换术风险的关联,并计算两组止痛药平均累积限定日剂量的增量变化。

主要发现

  • 双膦酸盐使用与全膝关节置换术风险显著降低相关(校正HR 0.76,95%CI 0.69-0.83,p<0.001)。
  • 随访≥24个月且MPR≥80%的患者中效应更显著(校正HR 0.66,p=0.048)。
  • 5年随访期间,双膦酸盐使用者的止痛药用量较非使用者显著减少(p<0.001,Chow检验)。

关键数值与推荐

  • 双膦酸盐使用者16,276例,未使用任何抗骨质疏松药物者123,791例。
  • 全膝关节置换术风险:校正HR 0.76(95%CI 0.69-0.83,p<0.001)。
  • 随访≥24个月且MPR≥80%者:校正HR 0.66(p=0.048)。
  • 止痛药用量减少:p<0.001(Chow检验)。
  • 证据等级:治疗性III级。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of bisphosphonates has been reported to have potential beneficial effects on knee osteoarthritis, but existing studies have limitations. The purpose of this study was to examine the association of bisphosphonate use with the risk of undergoing total knee arthroplasty and with the consumption of pain medication among osteoporotic patients with knee osteoarthritis. METHODS: We identified patients who were newly diagnosed with knee osteoarthritis among a cohort of patients with osteoporosis from 2009 to 2012 in the National Health Insurance Research Database in Taiwan. We further categorized these patients into 2 groups: those who were treated with bisphosphonates (bisphosphonate users) and those who were not treated with any anti-osteoporosis drug (nonusers). Bisphosphonate treatment adherence was calculated by the medication possession ratio (MPR) as the proportion of days of bisphosphonate treatment within a fixed duration; an MPR of ≥80% was considered high adherence. The primary and secondary outcomes of interest were undergoing total knee arthroplasty and the use of pain medication, respectively. Analyses using Cox proportional hazard models with propensity-score adjustment were performed to estimate the association between bisphosphonate use and the risk of undergoing total knee arthroplasty. The incremental change in the mean accumulated defined daily doses of pain medications among both bisphosphonate users and nonusers was calculated. RESULTS: We identified 16,276 bisphosphonate users and 123,791 nonusers of any anti-osteoporosis drug among the patients with osteoporosis who were newly diagnosed with osteoarthritis. Bisphosphonate use was significantly associated with a decreased risk of total knee arthroplasty (adjusted hazard ratio [HR], 0.76; 95% confidence interval [CI], 0.69 to 0.83; p < 0.001). In patients with a follow-up period of ≥24 months and an MPR of ≥80%, the effect size was significantly greater (adjusted HR, 0.66; p = 0.048). Over the 5 years of follow-up, we found a significantly greater decrease in the use of pain medication among bisphosphonate users than among nonusers (p < 0.001; Chow test). CONCLUSIONS: Among patients with osteoporosis and osteoarthritis, bisphosphonate use was associated with a significantly lower risk of total knee arthroplasty, especially in patients with high adherence and longer treatment duration. A lower consumption of pain medication was also found for bisphosphonate users among the patients with osteoporosis and osteoarthritis. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Fu SH, Wang CY, Yang RS, et al. Bisphosphonate Use and the Risk of Undergoing Total Knee Arthroplasty in Osteoporotic Patients with Osteoarthritis: A Nationwide Cohort Study in Taiwan. J Bone Joint Surg Am. 2017. PMID: 28590379. doi:10.2106/JBJS.16.00385

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。